Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer

导出学术成果认领

作者单位 Medicinal Bioconvergence Research Center, Advanced Institutes of Convergence Technology, Suwon, Gyeonggi 443-759, Korea;Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA ^[1] Department of Obstetrics and Gynecology, Samsung Medical Center and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine,Seoul 135-710, Korea ^[2] Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA ^[3] Medicinal Bioconvergence Research Center, Advanced Institutes of Convergence Technology, Suwon, Gyeonggi 443-759, Korea ^[4]

关键词 multi-tRNA synthetase complex AIMP2 splicing variant ovarian cancer chemoresistant cancer NF-κB

栏目名称 Articles

DOI 10.1093/jmcb/mjs018

发布时间 2013-06-05

基金项目

This work was supported in part by the Global Frontier grant (NRF-M1AXA002-2010-0029785) of National Research Foundation by the Korea Healthcare technology R&D project grant

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览7
被引4
下载0

分子细胞生物学报（英文版）

2012年4卷3期

164-173页

SCIMEDLINEISTICCSCDBP

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer

分子细胞生物学报（英文版）

相似文献

分子细胞生物学报（英文版）

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer

分子细胞生物学报（英文版）

相似文献

分子细胞生物学报（英文版）

相关期刊

检索历史清除